Topic: infectious disease
Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.
Sanofi, a hydroxychloroquine maker, is producing as much as it can amid the pandemic, but some workers are having to exit the line manufacturing line.
Oracle is working on a White House platform to promote off-label use of malaria drugs in COVID-19 and track patient outcomes, NYT reports.
Through weeks of sleepless nights and conference calls, Regeneron's research team is well positioned to solve COVID-19 with regulators' backing.
Biogen and Bayer deal with coronavirus rule-breakers in China. AbbVie's Kaletra fails COVID-19 study. Fosun licenses BioNTech's coronavirus vaccine.
Tennessee's self-described "patient zero" discussed hysteria, plus gestures of kindness, following his diagnosis.
As COVID-19 spreads, pharma's forcing sales reps to stay at home, subbing digital tools and virtual meetings for face-to-face physician visits.
Sanofi and Regeron aim to fast track arthritis med Kevzara for use in novel coronavirus patients with an immediate phase 2/3 global clinical program.
The White House Europe travel ban threatened to interrupt shipments of Novartis’ Kymriah, but Novartis found alternative delivery methods.
The state of New York will delay a key opioid bellwether trial in a move that could free drugmakers to aggressively pursue global settlements.